Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.58 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.57 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 6/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242620 | 0.90 | AURKA (0.59) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4234396 | 0.89 | BRD4 (0.59) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4234754 | 0.89 | LRRK2 (0.59) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4234274 | 0.89 | AURKA (0.59) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4238706 | 0.89 | AURKA (0.57) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4240930 | 0.89 | AURKA (0.61) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4238700 | 0.89 | AURKA (0.57) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4236731 | 0.88 | IGF1R (0.61) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4238681 | 0.87 | AURKA (0.56) | BRD4AURKAAURKBLRRK2PTK2 | |
| SCHEMBL4226614 | 0.87 | IGF1R (0.60) | BRD4AURKAAURKBLRRK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100894-A1 | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |